Effect to the Photobiomodulation in the Burning Mouth Syndrome
PBM-BMS
1 other identifier
interventional
40
1 country
1
Brief Summary
Introduction: Burning mouth syndrome (BMS) is a pathology with a low prevalence, affecting between 0.1% and 3.7% of the general population, the ratio between women and men is between 3 and 7:1. It is clinically characterized by a burning pain sensation, recurrent daily for more than 2 hours a day, persistent for more than 3 months and in a way that increases throughout the day and decreases at night, without presenting clinically evident causal lesions on the surface of the oral mucosa, nor changes in clinical sensory tests. The description of the symptomatology varies according to the patient and may be related especially to psychogenic factors. Patients report dry mouth/xerostomia and taste alterations, such as metallic or bitter taste. The most frequent location is on the tongue (tip and lateral borders), but it can also include the anterior palate, gingiva and lips. Since the etiopathogenic factors that produce BMS are not clear, it is difficult to make advances in therapy. The available treatments aim to control the multiple factors related to BMS, thus reducing the symptoms described by patients. Among them, the literature describes low level laser photobiomodulation. The success of the use of low level lasers for treatments in oral medicine is due to their biomodulatory activity and their ability to penetrate tissues. The analgesic action of laser radiation is due to the inhibition of nociceptive mediators and the release by the Central Nervous System (CNS) of endogenous analgesic substances such as endorphins, which hinders the transmission of the painful stimulus. It has been verified that low power laser radiation therapy can be effective in reducing symptoms in patients with BMS. Importantly, low power laser therapy is non-invasive, well tolerated by patients. Objectives: To confirm the hypothesis that the application of low power laser in the areas of oral burning can improve the symptomatology of BMS. Material and methods: We propose a clinical study in 38 patients with idiopathic BMS, prospective, randomized, double-blind. The study universe will be constituted by patients attended at the Oral Medicine, Oral Surgery and Implantology Unit of the Faculty of Dentistry of the University of Santiago de Compostela (USC). The Hospital Anxiety and Depression Scale (HADS), quality of life (OHIP-14) and subjective sensation of dry mouth xerostomia inventory (XI) questionnaires will be applied to all the patients, and the amount of saliva will be quantitatively determined by means of the unstimulated global saliva test (TSG-I) using a millimetric absorbent paper strip, at the beginning, at the end of treatment and at the re-evaluation at two and six months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2023
CompletedStudy Start
First participant enrolled
May 12, 2023
CompletedFirst Posted
Study publicly available on registry
May 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 15, 2024
CompletedApril 18, 2024
April 1, 2024
6 months
May 12, 2023
April 17, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain reported
To evaluate the effect of 808 nm diode laser radiation (infrared) applied intraorally on areas where patients report burning mouth. The degree of pain/burning reported by patients using a visual analogue scale (VAS). Scale from 0 to 10, where zero means no pain and ten means severe pain.
6 months
Secondary Outcomes (4)
Degree of anxiety of the patients
6 months
Quality of life of the patients
6 months
Subjective sensation of dry mouth
6 months
Quantitative measurement of saliva
6 months
Study Arms (2)
Laser Group (GL)
ACTIVE COMPARATORThe patients will be submitted to eight sessions of low power laser. The radiation emission will be performed according to the protocol.
Control Group (CG)
PLACEBO COMPARATORIn these patients the investigators will use the same protocol applied in the experimental group (time and application values) but the laser device will be turn off.
Interventions
Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients. * apex tongue: 3 points * lateral edge of the tongue: 4 points * tongue dorsum: 10 points * jugal mucosa: 8 points * labial mucosa: 5 points * hard palate: 8 stitches * soft palate: 3 stitches * gingiva or alveolar mucosa: 3 stitches per sextant. Time of 30 seconds in each application point, with dosage: 3 J/point.
The same protocol as the activated group
Eligibility Criteria
You may qualify if:
- Patients with a diagnosis of BMS and symptoms of at least 3 months duration;
- Clinical examination confirms clinically normal mucosa;
- Patients who are not undergoing treatment for BMS;
- Patients who, after being informed about the objectives and procedures of the investigation, agree and sign the informed consent form.
You may not qualify if:
- Patients with uncontrolled systemic diseases (ASA III, IV);
- Patients who have received previous radio and/or chemotherapy of the head and neck;
- Patients with secondary BMS, which is due to organic causes, such as biological factors, i.e. the presence of some bacteria or fungi, which have a direct irritant effect on the oral mucosa and are capable of triggering burning symptoms. Such conditions considered as differential diagnosis of primary BMS which are, oral candidiasis, erosive lichen planus, geographic tongue;
- Patients presenting systemic factors such as Sjögren's syndrome, untreated diabetes, or if they use drugs that cause oral burning;
- Patients presenting a VAS score below 3 out of 10.
- Removal criteria:
- Patients who for any reason fail to keep follow-up appointments.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universidad de Santiago de Compostela
Santiago de Compostela, A Coruña, 15785, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- One group will be lasered off and the other group will be lasered on.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 12, 2023
First Posted
May 23, 2023
Study Start
May 12, 2023
Primary Completion
October 30, 2023
Study Completion
January 15, 2024
Last Updated
April 18, 2024
Record last verified: 2024-04